EcoR1 Capital, LLC bought $40M of AKTS
director at Aktis Oncology, Inc.. 2,222,222 shares at an average of $18.00, traded Jan 12, 2026, filed Jan 12, 2026.
Score components
- +15RoleDirector
- +25Trade size$40.0M at market
- +10Relative to holdingsHoldings up 98%
- +10Price context0% above the 52-week low
- +15Cluster6 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -17.0%, 3m -20.3%, 6m +17.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000935836-26-000031, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 12, 2026 | CConversion Common Stockindirect: See Note | +2,270,879 | - | - | 2,270,879 | Jan 12, 2026 |
| Jan 12, 2026 | CConversion Common Stockindirect: See Note | +202,862 | - | - | 202,862 | Jan 12, 2026 |
| Jan 12, 2026 | CConversion Common Stockindirect: See Note | +128,506 | - | - | 128,506 | Jan 12, 2026 |
| Jan 12, 2026 | POpen-market purchase Common Stockindirect: See Note | +2,077,779 | $18.00 | $37M | 4,348,658 | Jan 12, 2026 |
| Jan 12, 2026 | POpen-market purchase Common Stockindirect: See Note | +144,443 | $18.00 | $2.6M | 347,305 | Jan 12, 2026 |
| Jan 12, 2026 | CConversion Series A Redeemable Convertible Preferred Stockderivativeindirect: See note | -9,913,810 | - | - | 0 | Jan 12, 2026 |
| Jan 12, 2026 | CConversion Series A Redeemable Convertible Preferred Stockderivativeindirect: See note | -997,299 | - | - | 0 | Jan 12, 2026 |
| Jan 12, 2026 | CConversion Series A Redeemable Convertible Preferred Stockderivativeindirect: See note | -488,891 | - | - | 0 | Jan 12, 2026 |
| Jan 12, 2026 | CConversion Series B Redeemable Convertible Preferred Stockderivativeindirect: See note | -2,397,500 | - | - | 0 | Jan 12, 2026 |
| Jan 12, 2026 | CConversion Series B Redeemable Convertible Preferred Stockderivativeindirect: See note | -102,500 | - | - | 0 | Jan 12, 2026 |
| Jan 12, 2026 | CConversion Class A Common Stockderivativeindirect: See note | +965,190 | - | - | 965,190 | Jan 12, 2026 |
| Jan 12, 2026 | CConversion Class A Common Stockderivativeindirect: See Note | +86,222 | - | - | 86,222 | Jan 12, 2026 |
Related signals
Other insiders at Aktis Oncology, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | Aktis Oncology, Inc. | Akos Czibere Chief Medical Officer | $259k 12,500 shares | -100% | |
| 45Moderate | Aktis Oncology, Inc. | Ken Herrmann director | $119k 4,856 shares | -100% | |
| 43Moderate | Aktis Oncology, Inc. | Ken Herrmann director | $77k 3,065 shares | -100% | |
| 60Notable | Aktis Oncology, Inc. | Akos Czibere Chief Medical Officer | $1.4M 50,000 shares | -100% | |
| 65Notable | Aktis Oncology, Inc. | Shulamit Ron-Bigger Chief Operating Officer | $1.4M 50,000 shares | -100% | |
| 60Notable | Aktis Oncology, Inc. | Ansbert Gadicke owner | $20M 1,112,777 shares | +12% | |
| 60Notable | Aktis Oncology, Inc. | Mpm Bioventures 2018, L.p. owner | $20M 1,112,777 shares | +12% | |
| 68Notable | Aktis Oncology, Inc. | Todd Foley director, owner | $4.2M 232,870 shares | +6% | |
| 68Notable | Aktis Oncology, Inc. | Helen Susan Kim director, owner | $15M 835,000 shares | +17% | |
| 60Notable | Aktis Oncology, Inc. | Vida Ventures II, LLC owner | $15M 835,000 shares | +17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.